Imipenem/cilastatin

ApprovedUNKNOWN

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Methicillin-resistant Staphylococcus Aureus

Conditions

Methicillin-resistant Staphylococcus Aureus, Pneumonia, Ventilator-Associated

Trial Timeline

Jun 1, 2011 → —

NCT ID

NCT01356472

About Imipenem/cilastatin

Imipenem/cilastatin is a approved stage product being developed by Pfizer for Methicillin-resistant Staphylococcus Aureus. The current trial status is unknown. This product is registered under clinical trial identifier NCT01356472. Target conditions include Methicillin-resistant Staphylococcus Aureus, Pneumonia, Ventilator-Associated.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01356472	Approved	UNKNOWN	Jun 1, 2011	—	Methicillin-resistant Staphylococcus Aureus

Competing Products

2 competing products in Methicillin-resistant Staphylococcus Aureus

See all competitors

Product	Company	Stage	Hype Score
Dalbavancin + Vancomycin + Oxacillin + Flucloxacillin + Cefadroxil + Clindamycin	AbbVie	Phase 3	77
Linezolid + Vancomycin	Pfizer	Pre-clinical	22

Other Products from Pfizer